ForSight Vision5 says it landed a $15 million Series C round for its Helios ocular insert.
ForSight Vision5, which is developing devices to treat front-of-the-eye conditions such as glaucoma and dry eye disease, said it pulled down a $15 million Series C round.
ForSight Vision5 is a spinout of ForSight Labs, a Menlo Park, Calif.-based incubator focused on developing ophthalmic treatments.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1f2HBb8
Cap comentari:
Publica un comentari a l'entrada